Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 255-261

  Scopelliti, Fernanda ^a   Pollicita, Michela ^a   Ceccherini Silberstein, Francesca ^a   Di Santo, Fabiola ^a   Surdo, Matteo ^a   Aquaro, Stefano ^b   Perno, Carlo Federico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

HIV; Integrase inhibitors; Lymphocytes; Macrophages; PBMC

Indexed keywords

IN 2; IN 5; INTEGRASE INHIBITOR; MK 2048; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; RALTEGRAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS INHIBITION;

APOPTOSIS; CELLS, CULTURED; HIV CORE PROTEIN P24; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; LYMPHOCYTES; MACROPHAGES; MICROBIAL SENSITIVITY TESTS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80054854717     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.008     Document Type: Article

References (55)

1. Alexaki A., Liu Y., Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 2008, 6:388-400.
2. Aquaro S., Perno C.F. Assessing the relative efficacy of antiretroviral activity of different drugs on macrophages. Methods Mol. Biol. 2005, 304:445-453.
3. Aquaro S., Perno C.F., Balestra E., Balzarini J., Cenci A., Francesconi M., Panti S., Serra F., Villani N., Caliò R. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J. Leukoc. Biol. 1997, 62:138-143.
4. Aquaro S., Caliò R., Balestra E., Bagnarelli P., Cenci A., Bertoli A., Tavazzi B., Di Pierro D., Francesconi M., Abdelahad D., Perno C.F. Clinical implications of HIV dynamics and drug resistance in macrophages. J. Biol. Regul. Homeost. Agents 1998, 12:23-27.
5. Aquaro S., Bagnarelli P., Guenci T., De Luca A., Clementi M., Balestra E., Caliò R., Perno C.F. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 2002, 68:479-488.
6. Aquaro S., Caliò R., Balzarini J., Bellocchi M.C., Garaci E., Perno C.F. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 2002, 55:209-225.
7. Badley A.D., Dockrell D., Simpson M., Schut R., Lynch D.H., Paya P. Macrophage-dependent apoptosis of CD4+ T Lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 1997, 185:55-64.
8. Bagnarelli P., Valenza A., Menzo S., Sampaolesi R., Varaldo P.E., Butini L., Montroni M., Perno C.F., Aquaro S., Mathez D., Leibowitch J., Balotta C., Clementi M. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J. Virol. 1996, 70:7603-7613.
9. Cassol E., Alfano M., Biswas P., Poli G. Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J. Leukoc. Biol. 2006, 80:1018-1030.
10. Ceccherini-Silberstein F., Malet I., D'Arrigo R., Antinori A., Marcelin A.G., Perno C.F. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009, 11:17-29.
11. Cenci A., Perno C.F., Menzo S., Clementi M., Erba F., Tavazzi B., Di Pierro D., Aquaro S., Caliò R. Selected nucleotide sequence of the pol gene of the monocytotropic strain HIV type 1 BaL. AIDS Res. Hum. Retroviruses 1997, 13:629-632.
12. Charpentier C., Karmochkine M., Laureillard D., Tisserand P., Bélec L., Weiss L., Si-Mohamed A., Piketty C. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med. 2008, 9:765-770.
13. Chomont N., El-Far M., Ancuta P., Trautmann L., Procopio F.A., Yassine-Diab B., Boucher G., Boulassel M.R., Ghattas G., Brenchley J.M., Schacker T.W., Hill B.J., Douek D.C., Routy J.P., Haddad E.K., Sékaly R.P. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 2009, 15:893-900.
14. Chomont N., Da Fonseca S., Vandergeeten C., Ancuta P., Sékaly R.P. Maintenance of CD4+ T-cell memory and HIV persistence. Keeping memory, keeping HIV. Curr. Opin. HIV AIDS 2011, 6:30-36.
15. Chun T.W., Finzi D., Margolick J., Chadwick K., Schwartz D., Siliciano R.F. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1995, 1:1284-1290.
16. Chun T.W., Justement J.S., Lempicki R.A., Yang J., Dennis G., Hallahan C.W., Sanford C., Pandya P., Liu S., McLaughlin M., Ehler L.A., Moir S., Fauci A.S. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl. Acad. Sci. USA 2003, 100:1908-1913.
17. Cocohoba J., Dong B.J. Raltegravir: the first HIV integrase inhibitor. Clin. Ther. 2008, 30:1747-1765.
18. Coleman C.M., Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 2009, 6:51.
19. Croteau D., Letendre S., Best B.M., Ellis R.J., Breidinger S., Clifford D., Collier A., Gelman B., Marra C., Mbeo G., McCutchan A., Morgello S., Simpson D., Way L., Vaida F., Ueland S., Capparelli E., Grant I., CHARTER Group Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob. Agents Chemother. 2010, 54:5156-5160.
20. Dieffenbach C.W., Fauci A.S. Thirty years of HIV and AIDS: future challenges and opportunities. Ann. Intern. Med. 2011, 154:766-771.
21. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
22. Garaci E., Caroleo M.C., Aloe L., Aquaro S., Piacentini M., Costa N., Amendola A., Micera A., Caliò R., Perno C.F., Levi-Montalcini R. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc. Natl. Acad. Sci. USA 1999, 96:14013-14018.
23. Garaci E., Aquaro S., Lapenta C., Amendola A., Spada M., Covaceuszach S., Perno C.F., Belardelli F. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice. Proc. Natl. Acad. Sci. USA 2003, 100:8927-8932.
24. Gendelman H.E., Narayan O., Kennedy-Stoskopf S., Kennedy P.G., Ghotbi Z., Clements J.E., Stanley J., Pezeshkpour G. Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J. Virol. 1986, 58:67-74.
25. Goffinet C., Allespach I., Oberbremer L., Golden P.L., Foster S.A., Johns B.A., Weatherhead J.G., Novick S.J., Chiswell K.E., Garvey E.P., Keppler O.T. Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. J. Virol. 2009, 83:7706-7717.
26. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287:646-650.
27. Herbein G., Mahlknecht U., Batliwalla F., Gregersen P., Pappas T., Butler J., O'Brien W.A., Verdin E. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998, 395:189-194.
28. Herbein G., Gras G., Khan K.A., Abbas W. Macrophage signaling in HIV-1 infection. Retrovirology 2010, 9:7-34.
29. Hicks C., Gulick R.M. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 2009, 48:931-939.
30. Kaul R., Dong T., Plummer F.A., Kimani J., Rostron T., Kiama P., Njagi E., Irungu E., Farah B., Oyugi J., Chakrabarty R., MacDonald K.S., Bwayo J.J., McMichael A., Rowland-Jones S.L. CD8 (+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. 2001, 107:1303-1310.
31. Kelly J., Beddall M.H., Yu D., Iyer R.S., Marsh J., Wu Y. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 2008, 372:300-312.
32. Kogan M., Rappaport J. HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 2011, 13:8-25.
33. Little, S., Drusano, G., Schooley, R, Haas, D., Kumar, P., Hammer, S., McMahon, D., Squires, K., Asfour, R., Richman, D., Chen, J., Saah, A., Leavitt, R., Hazuda, D., Nguyen, B.Y., and Protocol 004 Study Team, 2005. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections Boston, Massachusetts - February 22-25, 2005.
34. Markowitz M., Morales-Ramirez J.O., Nguyen B.Y., Kovacs C.M., Steigbigel R.T., Cooper D.A., Liporace R., Schwartz R., Isaacs R., Gilde L.R., Wenning L., Zhao J., Teppler H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 2006, 43:509-515.
35. McGrath M.S. T-cells and macrophages in HIV disease. Clin. Rev. Allergy Immunol. 1996, 14:359-366.
36. McNeely M., Christ F., Thys W., Debyser Z. Targeting the HIV integration process in antiviral therapy. J. HIV Ther. 2008, 13:83-92.
37. Michelini Z., Galluzzo C.M., Negri D.R., Leone P., Amici R., Bona R., Summa V., Di Santo R., Costi R., Pommier Y., Marchand C., Palmisano L., Vella S., Cara A. Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. J. Virol. Methods 2010, 168:272-276.
38. Moltó J., Valle M., Back D., Cedeño S., Watson V., Liptrott N., Egan D., Miranda C., Barbanoj M.J., Clotet B. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob. Agents Chemother. 2011, 55:72-75.
39. Murray J.M., Emery S., Kelleher A.D., Law M., Chen J., Hazuda D.J., Nguyen B.Y., Teppler H., Cooper D.A. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007, 21:2315-2321.
40. Orenstein J.M., Meltzer M.S., Phipps T., Gendelman H.E. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 1988, 62:2578-2586.
41. Perno C.F., Bergamini A., Pesce C.D., Milanese G., Capozzi M., Aquaro S., Thaisrivongs S., Tarpley W.G., Zon G., D'Agostini C., Rocchi G., Garaci E., Caliò R. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J. Infect. Dis. 1998, 168:1148-1156.
42. Pierson T., McArthur J., Siliciano R.F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 2000, 18:665-708.
43. Pollicita M., Muscoli C., Sgura A., Biasin A., Granato T., Masuelli L., Mollace V., Tanzarella C., DelDuca C., Rodinò P., Perno C.F., Aquaro S. Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line. BMC Neurosci. 2009, 10:51.
44. Pomerantz R.J. Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. AIDS 2001, 15:1201-1211.
45. Pomerantz R.J., Horn D.L. Twenty years of therapy for HIV-1 infection. Nat. Med. 2003, 9:867-873.
46. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
47. Schafer J.J., Squires K.E. Integrase inhibitors: a novel class of antiretroviral agents. Ann. Pharmacother. 2009, 44:145-156.
48. Serrao E., Odde S., Ramkumar K., Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of " me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25.
49. Sharova N., Swingler C., Sharkey M., Stevenson M. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J. 2005, 24:2481-2489.
50. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Zhao J., Chen J., Ryan D.M., Rhodes R.R., Killar J.A., Gilde L.R., Strohmaier K.M., Meibohm A.R., Miller M.D., Hazuda D.J., Nessly M.L., DiNubile M.J., Isaacs R.D., Nguyen B.Y., Teppler H., BENCHMRK Study Teams Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359:339-354.
51. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., Jones P., Kinzel O., Laufer R., Monteagudo E., Muraglia E., Nizi E., Orvieto F., Pace P., Pescatore G., Scarpelli R., Stillmock K., Witmer M.V., Rowley M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51:5843-5855.
52. Vacca, J., Wai, J., Fisher, T., Embrey, M., Hazuda, D., Miller, M., Felock, P., Witmer, M., Gabryelski, L., Lyle, T., 2007. Discovery of MK-2048-subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors. International AIDS Society (IAS) Conference 22-25 July, Rio De Jainero.
53. Venzke S., Keppler O.T. Role of macrophages in HIV infection and persistence. Expert Rev. Clin. Immunol. 2006, 2:613-626.
54. Wai J.S., Kim B., Fisher T.E., Zhuang L., Embrey M.W., Williams P.D., Staas D.D., Culberson C., Lyle T.A., Vacca J.P., Hazuda D.J., Felock P.J., Schleif W.A., Gabryelski L.J., Jin L., Chen I.W., Ellis J.D., Mallai R., Young S.D. Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17:5595-5599.
55. Yadav A., Collman R.G. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J. Neuroimmune Pharmacol. 2009, 4:430-447.